Sanaka T, Sugino N
Department of Medicine, Kidney Center, Tokyo Women's Medical College.
Nihon Jinzo Gakkai Shi. 1991 Nov;33(11):1153-9.
Recombinant human growth hormone (r-hGH), 1 U/kg body weight/week, was administered subcutaneously for 2-4 weeks to two end stage renal disease patients with severe malnutrition. Following r-hGH, there were significant increase in hematocrit level and serum concentration of albumin, IGF-1 and GH, and decrease of urea nitrogen. It was concluded that r-hGH exerts a therapeutic effect to nutritional status in renal failure patients by improving severe hypoalbuminemia, susceptibility to infectious disease, intractable ascites and so on.
重组人生长激素（r-hGH），每周1单位/千克体重，皮下注射给药2至4周，用于两名患有严重营养不良的终末期肾病患者。给予r-hGH后，血细胞比容水平以及白蛋白、胰岛素样生长因子-1（IGF-1）和生长激素（GH）的血清浓度显著升高，尿素氮降低。得出的结论是，r-hGH通过改善严重低白蛋白血症、对传染病的易感性、顽固性腹水等，对肾衰竭患者的营养状况发挥治疗作用。
